high-bleeding-risk individual and impaired renal function 11ġ5 mg daily if ClCr 30–49 ml/min Avoid if ClCr 80 years, weight 133 microM/L.low bleeding risk and normal renal function.Heart failure or left ventricular dysfunction (ejection fraction 75years or with ClCr 30–49 ml/min.Prevention of stroke or systemic embolism in a patient with non-valvular atrial fibrillation* who is at moderate-to-high risk of developing stroke or systemic embolism as evidenced by one or more of the following risk factors: Current PBS-approved indications for NOACs 1 The new oral anticoagulants (NOACS) offer an alternative to warfarin therapy for selected patients, but as with all anticoagulants, they can potentially cause serious bleeding. VKAs have also been used extensively over the past 50 years in the treatment and prevention of deep venous thrombosis, pulmonary embolism and for the prevention of thromboembolism in mechanical valves. Oral anticoagulation in the form of vitamin K antagonists (VKAs) is a well-established treatment for stroke prevention in AF. A number of different medications, including oral anticoagulants and antiplatelet agents, are increasingly being used in the treatment of different clinical conditions.
0 Comments
Leave a Reply. |